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Abstract 
 
With cancer representing 13% of all deaths worldwide, it is the second 
biggest cause of death. Cancers of the brain despite being a rare cancer 
has shown increased occurrence rates of 39% in the last 40 years. This 
increased rate is due to difficulty in treating brain cancers. 
Variation of the genome makes some individuals more susceptible to 
cancer than others. Brain tumors form familial mutations that are 
passed down to offspring, this is evidently seen throughout the human 
population and can be linked to an individual’s racial background. This 
research looked at a protein associated with glioma formation (merlin) 
and the inheritance of that protein to deduce whether cancer 
associated proteins follow Mendelian genetics or if epigenetics carries 
an important role. Merlin is encoded by the NF2 gene, and mutation 
causes the glioma predisposition, neurofibromatosis in humans. Merlin 
is seen homologous within both humans and Drosophila melanogaster 
(D. melanogaster) proving D. melanogaster to be a suitable model 
organism to study merlin. In this study three populations of D. 
melanogaster were bred, each with a distinct allele of merlin (Mer 3, 
Mer 4 and Wild-Type Mer), these alleles represented the variation 
within the human population; races. Populations were crossed to 
produce hybrid populations of the three variants of merlin. The 
mortality and survival rates were calculated and together with the 
expected phenotypic ratio showed that the drosophila were often 
surviving in higher rates than were expected and thus natural selection 
is suggested to be at work with the evolution of a population based on 
a gene for a cancerous phenotype. 
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1.1 The Origins of Cancer 
 
The human body is a multi-cellular organism, with many types of cells 
that are often specialized to a specific role. These individual roles work 
as a collective, thus maintaining the body’s natural ecosystem and 
homeostasis. As with all living things, the human body ages and the 
cells die by natural causes including apoptosis, necrosis and 
autophagy, which must be replaced. Cells undergo mitotic division by 
which they duplicate and then separate their genome and organelles, 
dividing into two identical daughter cells (See Figure 1.1).  
 
Figure 1. 1 – Adapted from Marston and Amon, 2004 shows a cell going through cell division. The 
cell duplicates its’ genome/chromosome(s) and then divides into two identical daughter cells 
As cells replicate their genome, mistakes may occur within the DNA 
code. These mistakes are mutations, where one nitrogenous base is 
replaced by another. Though minor, these mistakes may result in a 
change of the protein in which that genomic segment is encoded for. 
Similarly, other forces such as an environmental change can 
alter/mutate DNA. Insignificant to the origin, DNA mutations are often 
dealt with efficiently by the body’s DNA repair mechanisms (Sudhakar, 
2009). The mechanisms that repair DNA work both effectively and 
efficiently and repair most mutations that occur. Despite the sufficient 
repairs that cells can make to their DNA some cells cannot correct the 
genome, and this can result in the cell often over or under producing a 
protein or altering a mechanism or pathway (Iyama and Wilson, 2013). 
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The changes to proteins and pathways often add up, until a cell has 
several mutations in key areas, which will be discussed below. This cell 
with its’ multitude of mutations can be deemed ‘cancerous’. All is not 
lost, however, as again most cells that reach this stage would be swiftly 
removed by the bodies adept immune response.  The cancerous cells 
would need further mutations to its’ recognition to evade immune 
destruction (Sudhakar, 2009). Ultimately, this would require 
mutations to the proteins that are used for cells to recognize each 
other and recognize their condition as either viable or non-viable 
(Vinay, et. Al,. 2015). Cells that are non-viable would ‘appear’ this way 
to the immune response and be removed. However, a mutation in this 
recognition system would allow a non-viable cancer cell to appear 
functionally normal and the immune response would swiftly move on, 
leaving the cancer cell unharmed. From here cancer cells would rapidly 
begin to proliferate due to mutations in the control of their cell cycle, 
which would lead to tumour formation (Sudhakar, 2009). 
Cancer as a disease is seen throughout the phylogenetic tree of multi-
cellular organisms due to replication mutations causing tumors, both 
benign and cancerous (Ewald and Swain Ewald, 2015). The disease’s 
origin would have occurred with the evolution of replication, a 
fundamental principle that began with the transition from chemistry to 
biology; life. The transition of single cell becoming multi-cellular and 
specializing would have therefore produced cancer as seen within 
plants and most of the animal kingdom. Potential fossil evidence of 
cancer and even early descriptions may show that cancer was 
described by our oldest of human ancestors (Odes et al., 2016).  
Firstly described as an imbalance of fluids, the idea of cancers’ origin 
has vastly shifted throughout the centuries. Theories such as cancer 
arising from trauma or a parasite have all led to modern times with 
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malignant cell theory to the introduction of genes and thus the process 
described above (Sudhakar, 2009).  
Cancer as a disease is now defined by its’ over-proliferative 
capabilities. This is a result of the aforementioned inability of a cell to 
repair its’ mutated DNA and as mentioned, mutations in key areas of 
the cell’s genome are what birth a cancerous cell.  
In 2000 Hanahan and Weinberg deduced that most cancers, if not all, 
required mutations in various traits to be deemed cancerous. Similarly 
to above, key areas of a cell’s genome must mutate for cancer to occur. 
Therefore, the authors assimilated that there were six ‘Hallmarks of 
cancer’ (see Figure 1.2.) 
 
Figure 1. 2 - Taken from Hanahan and Wienberg, 2000. The figure shows the six hallmarks of 
cancer, the cell traits or processes that many cancers show a mutation in. 
Hanahan and Weinberg further stated that these six hallmarks were 
essential for cancer formation. Self-sufficiency in growth signals and 
insensitivity to anti-growth signals work in unison, as a mutation to 
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the cell’s growth-signal recognition allows it to ignore signals to stop 
growing and constantly activate signals to grow (Hanahan and 
Weinberg, 2000). These in turn allow the next pair to commence; 
evading apoptosis and limitless replicative potential (Hanahan and 
Weinberg, 2000). Evading apoptosis or programmed cell death results 
in the cell ignoring signals to begin to die at the same time following 
signals to both grow, and to continue replicating. The four hallmarks 
discussed, seen in figure 1.2, allow the cells to grow and replicate to 
begin forming a tumour. However, with rapid growth comes the need 
for high quantities of oxygen and energy in the form of glucose. It is 
therefore essential for the fifth hallmark to be present, sustained 
angiogenesis (Hanahan and Weinberg, 2000).  
Angiogenesis is the formation of new blood vessels from currently 
existing ones. Cancerous tumours can reach a growth limit, restrained 
by their need for excessive oxygen and glucose. A tumour would 
remain in this restraint if it were not for another mutation.  A mutation 
in angiogenesis-based genes allows the tumor to begin manipulating 
blood vessels, producing its own supply. This new supply of blood can 
unrestraint the tumor, increasing its growth capacity. This lastly brings 
in the sixth hallmark, tissue invasion and metastasis. Without 
angiogenesis or a blood vessel in close proximity, cancers will remain 
in the area they have initially formed. However, with a mutation in the 
cell’s ability to stay connected to other cells, a single cancerous cell can 
become dislodged and enter the blood vessel. Further mutations to this 
dislodged cell allow it to take hold in a new location and continue its 
growth and replication causing secondary tumours. 
In 2011 Hanahan and Weinberg produced a follow-up journal to their 
hallmarks and discussed the knowledge gained about them in the 
decade between that and their previous papers. In this paper they 
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discuss two further hallmarks, which they deem ‘emerging hallmarks’. 
Both emerging hallmarks have been mentioned, avoiding immune 
destruction and deregulating cellular energetics (see Figure 1.3.) 
 
Figure 1. 3- Taken from Hanahan and Wienberg, 2011. The figure shows the two emerging 
hallmarks of cancer, and two enabling characteristics of cancer. These are an addition to the 
previous six hallmarks, the cell traits or processes that many cancers show a mutation in. 
The ability to avoid the immune response by cancer cells has been 
discussed above and would be utilised the most during a cell’s 
migration through the blood stream i.e metastasis, and the invasion of 
new areas of the body (Hanahan and Weinberg, 2011). The 
requirement for high levels of oxygen and glucose has been stated 
earlier in this chapter. However the emerging hallmark results in a 
cancerous cell having mutations in the structure of the energy 
pathways and thus a change in these may allow more glucose uptake. 
This potential increase of glucose would in turn fuel cancerous growth, 
replication and metastasis (Hanahan and Weinberg, 2011). 
Enabling characteristics are those traits that appear at the beginning of 
cancer. Genomic instability and mutation is by far the most extensively 
researched of these as the mutations of the unstable genome are what 
produce the further hallmarks. The inflammatory response under 
taken by the innate immune system, can promote the other hallmarks, 
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producing a cancer positive environment, allowing cancer to take hold 
more easily (Hanahan and Weinberg, 2011).   
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1.2 Epidemiology/Cancer Statistics and Treatments 
 
An estimated 8.2 million people die from cancer each year 
representing globally, 13% of worldwide deaths. Cancer is the second 
biggest cause of death, after cardiovascular diseases. Figure 1.4, shows 
the incidences of cancer worldwide in 2012. Note that genders have 
not been defined and age has been standardised (World Health 
Organisation, 2012).   
Estimated age-standardized rates (World) of incidence cases, 
both sexes, all cancers excluding non-melanoma skin, worldwide 
in 2012 
Figure 1. 4– Map showing the estimate cases of cancer worldwide in 2012 taken from World health 
Organisation. Key is the number of case per 100,000. 
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The cost of cancer is of major concern worldwide, but can be seen with 
specificity to the NHS in the UK (Department of Health GOV.UK, 2017). 
The government policy 2010-2015 on cancer research and treatment 
gives the following statistics (Department of Health GOV.UK, 2017).  
Annually, 250,000 people are diagnosed with cancer and, 130,000 
people die as a result of cancer in the UK (Department of Health 
GOV.UK, 2017).  The document produced by the Department of Health 
states that despite the UK’s wealth, the survival rates are not 
improving as significantly as countries of a similar wealth. Lastly the 
Department of Health document discusses some monetary figures. The 
NHS annually spends £5 billion on cancer services. However, the cost 
overall to society, including further treatment and loss of production is 
approximated at £18.3 billion annually (Department of Health GOV.UK, 
2017). 
With statistics this high, research into cancer is required to allow for 
new concepts and potential treatments to be introduced as well as 
providing a sustainable cost to cancer services and treatment. 
The current treatments of cancer fall into three main areas: 
radiotherapy, chemotherapy and surgery (World Health Organisation, 
2017). Radiotherapy is treatment through radiation usually in the form 
of rays. These can include X-rays and electron beams. Chemotherapy is 
treatment through chemicals and substances. Chemotherapy often 
targets one of the hallmarks mentioned above. For example, 
temozolomide targets cancer cell DNA during its replication, 
vincristine targets the cells as they replicate, and bevacizumab is used 
to stop angiogenesis (National Cancer Institute, 2017). In the 
aforementioned Department of Health policy document 2010-2015, 
additional funds to treatment were discussed for the future. £23 
million invested to improve radiotherapy and £250 million to develop 
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proton beam therapy. Increased funds have been available through 
2010-2015, and further increases were available through 2016 and 
beyond that, as NHS England supply funds to the NHS sectors. From 
treatments and funding for medical care, comes a second major aspect 
to patients, their quality of life (QoL).  Quality of life is significantly 
reliant on the cancer type and the amount of pain that the patient feels, 
with demographics such as age or income having little or no 
correlation to QoL (Heydarnejad et al. 2011). Last to discuss is some of 
the underlying factors to cancer. Highlighted in the above Department 
of Health policy were apparent changes to society and the population, 
which in turn are changing cancer statistics but are not being 
emphasized enough. The two, mainly focused on, are smoking and 
improving diet/reducing obesity (Department of Health GOV.UK, 
2017). 
Cancer treatments are often held back by the extensive studies that 
must be completed but more so by the research that leads to new 
potential treatment and therapeutic options. 
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1.3 The Inheritance of Cancer 
 
Changes within a genome are often seen as the root of cancers because 
without the multitude of mutations to the genome, a cell cannot 
become cancerous (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011).    However, it is important to discuss that many cells 
will gain a mutation through mistakes in cell division, as mentioned 
above, and will not become cancerous. Without several mutations in 
the key areas of the genome i.e. those areas that encode proteins active 
or associated with the hallmarks of cancer, many cells do not become 
cancerous (Hanahan and Weinberg, 2000).  The cells that do gain 
mutations, be it one or numerous, will usually be detected by the body 
and enter apoptosis or be subject to immune destruction. (Hanahan 
and Weinberg, 2000; Hanahan and Weinberg, 2011).   
The fundamental statement to the theory of evolution, proposed by 
Charles Darwin in ‘On the Origin of Species’ in 1859, which is now 
known to be the main factor for evolution is mutation of the genome 
and variation. 
“It seems pretty clear that organic beings must be exposed during 
several generations to the new conditions of life to cause any 
appreciable amount of variation” – Charles Darwin, 1859. 
Exposure to new conditions causes variation and this was apparent to 
Darwin and is still key to the entire central dogma of molecular 
biology. Cancer can only occur by variation, often this variation is 
causes by a new or changing condition.  
Cellular mutation is often anchored to the individual person/patient 
due to the mutated cell location i.e. non-sex cells. In contrast, a 
mutation within the sex cells can be passed down to an offspring. All 
cells within the body have the same genome within them, so if a 
mutation inherited increases a person’s chance of cancer, this can in 
22 
 
turn be passed down and form a hereditary cancer. This can be 
explained by the schematics below. 
Described below is three short sections of single-stranded DNA, they 
have no scientific relevance and are used only as an explanation. 
The first line is the DNA seen in many of the cancer cells, in which a key 
gene and therefore protein is a mutation that causes cancer. 
A) 
 
 
The second row is the DNA seen in non-cancerous cells, in which the 
gene and protein continues its normal function. 
B) 
 
 
Looking at the two lines of code (A and B), it is clear that the bases are 
dissimilar and would require many mutations to the one section of 
DNA to mutate this single protein. Of the six DNA bases shown, only 
one (the second base, thymine) is the same between both segment A 
and B. This means five point mutations would be required to healthy, 
non-cancerous segment B for it to become cancerous segment A. 
The last segment of DNA (C) is a healthy, non-cancerous segment and 
still encodes the protein that functions normally. However, comparing 
this segment (C) to the first (A) it is clear that they are more similar 
and in fact only one change of base (the second base, cytosine to a 
thymine) is required to mutate this healthy, non-cancerous DNA 
segment into the cancerous one. 
C) 
  
 
A T T C G A 
T T G G C T 
A C T C G A 
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From this, it is clear that throughout humanity many variations of the 
same DNA code exists and some individuals carry a variation that is 
more similar to the cancerous form and would therefore require less 
mutation to allow a cell to become cancerous. 
In 1971, Alfred Knudson conceived the theory known as the two-hit 
hypothesis. Knudson’s theory not only stated that cancer is an 
accumulation of many mutations, but Knudson explained how cancer 
can be inherited and develop later in life. It is important to note that a 
mutation of one chromosome would often result in the cell utilizing the 
second chromosome and thus cancer can often be avoided through this 
action. However, if the second chromosome then becomes mutated, the 
outcome is inevitable, and cancer will form. The variations of a 
chromosome, which produce different phenotypes, are called an allele.  
Knudson stated that cancer has two categories in his hypothesis, 
namely familial and sporadic. Familial cancer is an inherited mutation 
in one chromosome, where the second becomes mutated during 
development. Sporadic cancer, on the other hand, is where no mutated 
alleles are inherited and instead both chromosomes mutate within 
development at different stages of cell differentiation. In 2012 Lee 
highlighted Knudson’s theory and its uses in modern disciplines and 
principals. Lee discussed genotypic mutation, epigenetics and 
modification of gene expression; concepts that are now often discussed 
with cancer and that the concepts require research with regards to 
cancer inheritance (Lee et al. 2012). 
A new study has highlighted that up to 10% of all cancers are non-
sporadic and are due to a hereditary links (Romero and Castro, 2017).  
The authors continued by stating that high-throughput sequencing has 
revealed many new germ line cancers that were previously thought to 
be only somatic and anchored to the individual patient with no 
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possibility of being passed down a generation (Romero and Castro, 
2017). Many genetic causes related to hereditary cancer are unknown 
this can be seen in figure 1.5, taken from the study by Romero and 
Castro, 2017.  
 
Figure 1. 5- Taken from Romero and Castro, 2017. Two pie charts to show the genetic causes of 
hereditary breast and ovarian cancer. Note the unknown genetic cause to hereditary breast and 
ovarian cancer to be 59% and 76.4% respectively. 
The authors noted that it is expected for many more genes to be 
revealed to show a link to both breast and ovarian cancer (Romero and 
Castro, 2017). Transferring this concept to other cancer types would 
not be difficult with most other cancer types expected to have a similar 
hereditary disposition. 
 
 
 
 
 
 
 
 
 
 
 
25 
 
1.4 Cancers of the Brain – Glioma 
 
The human brain is the feature that is always discussed in regards to 
human evolution and the differences in brain size to the rest of the 
animal kingdom. But despite this, most animals have similarly 
structured brains and entire nervous systems (Ledda et al., 2004). The 
nervous system evolved to complete the role of various action 
potentials in eukaryotes as single-celled organisms became multi-
cellular organisms. The brain was born from collections of neuronal 
cell bodies/ ganglia and has rarely changed throughout vertebrate 
evolution. This can be seen in the neuronal cell study on reptiles and 
mammals (Ledda et al., 2004). 
With the evolution of the brain, so followed brain tumours/ brain 
cancer. Brain cancers are classified into various types and recently the 
classification has been revised from the 2007 edition of the ‘World 
Health Organisation (WHO) classification of tumours of the Central 
Nervous System’ (Shown in the appendix). The new classification has 
particularly focused on molecular parameters in sequence with 
histology. The latter was the sole technique for classification prior to 
this (Louis et al., 2016). The new addition of WHO classification shows 
similarity to the previous 2007 addition with major brain tumour 
groups including astrocytic tumours, oligodenroglial tumours and 
ependymal tumours, the former seen as the largest group (Louis et al., 
2007; Louis et al., 2016). 
Astrocytic tumours are again split into various sub-types including 
glioblastoma, astrocytoma, pilocytic astrocytoma etc. However, this is 
usually kept at two major factions of astrocytoma, the malignant form; 
glioblastoma multiforme (GBM), and non-GBM. It is important to note 
that astrocytomas are the largest group of brain tumours because 
astrocytes are the most abundant cell within the brain. 
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Neuronal cells are split into nerve cells and glial cells. Nerve cells send 
signals/action potentials, conversely, glial cells send no action 
potential. Glial cells make up much of the brains’ mass and include the 
astrocyte mentioned, oligodendrocytes and microglia, amongst others. 
Astrocytes form the blood brain barrier and act as the mediator 
between the blood stream and other brain cells. Microglia are 
phagocytic, which allows them to perform the role of an immune cell 
and act as the brains personal immune system. Oligodendrocytes form 
various sheaths around the nerve cells, allowing for faster action 
potentials. When cancer occurs within these glial cells, it is deemed 
glioma 
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1.5 Brain Tumour Treatments and Statistics 
 
The treatment of brain tumours is similar to the treatment of all 
cancers overall with radiotherapy, chemotherapy and surgery being 
the main routes of treatment (Department of Health GOV.UK, 2017). 
The outcome for brain tumours in both treatment and survival often 
relies on a combination of factors: position within the brain, type of 
brain tumour, and the size and shape. The grade of the tumour is key, 
and all of the types and sub-types previously discussed are graded I-V. 
The table below shows the WHO grading in 2007 (Louis et al., 2007). 
 
Grade I Low Proliferation Potential cure 
following surgery 
No infiltration 
Grade II Low Proliferation Often recur following 
surgery 
Can Infiltrate 
Grade III Fast proliferation Often recur following 
chemotherapy and 
radiation 
Malignant 
Grade IV Rapid proliferation Rapid progression of 
disease with most 
treatments, often 
fatal outcomes 
Highly malignant 
Table 1.1 - The World health Organisation brain tumor grading system from 2007. Adapted from 
Louis et al., 2007. 
 
It is the difficulty in treatment that makes brain tumours so 
detrimental to patient lives. Moreover, successful treatment is often 
shrouded by the repetitive nature of recurrent tumours. Coupled with 
low survival, brain tumours are fundamentally a destructive and 
horrific disease. 
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Despite representing only 3% of all cancer types, tumours of the brain 
and nervous system, as mentioned earlier, can often be the most 
difficult. The difficulty around treatment and survival has been 
mentioned, and these difficulties have resulted in the rate of brain 
tumours increasing each year. Below is a figure from Cancer Research 
UK representing the rate of brain tumours per year from 1979 – 2013. 
 
Figure 1. 6– A graph showing the rates of brain tumours per 100,000 people between the years 
1979 and 2013. Sex is shown both separated and together (Cancer research UK, 2017). 
Cancer Research UK estimates this increase at 39% since the first date 
shown. Despite a slight difference in the sexes, with males having a 
higher rate than females, both show a similar trend (Cancer Research 
UK, 2017). With brain tumour rates drastically increasing, and survival 
rates increasing at a much slower rate, brain cancers are rapidly 
becoming one of the most problematic diseases with treatments often 
showing little or no destruction of the tumour. Finally, more issues 
arise from the cancer’s position within the body, the brain. Access to 
treatment and surgery is often problematic due to location and the 
need for treatment/ drugs to cross the blood-brain barrier. The blood-
brain barrier hinders more than 98% of drugs from reaching and 
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treating the brain (Anand et al., 2015). This difficulty is therefore 
shown in survival. 
A treatment into brain tumours that is advancing rapidly is 
immunotherapy, where treatment involves the use of the patients own 
immune system as a form of cancer treatment. Immunotherapy 
treatment is becoming increasingly popular in the treatment of GBM, 
and thus research has focused on its’ current applications and future 
use in cancer treatment (McGranahan et al., 2017). McGranahan’s 
research was focused on the history of immunotherpy’s and its’ 
current uses and applications. The article concluded that the history of 
immunotherapy in brain tumour treatment was a reminder of the 
treatment risks associated with immunotherapy. The authors finished 
with stating that the recent gain of knowledge and development into 
immunotherapy holds great hope for the future and all the possible 
advancements in glioma treatments (McGranahan et al., 2017). 
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1.6 Brain Tumours – Racial Bias Statistics 
 
With an increase of occurrence and lack of an effective treatment, 
brain tumours are an area of research that is growing but needs more 
study.  
In 2011 Dubrow and Darefsky began reviewing the statistical data of 
brain tumours. From their findings, they hypothesised that the 
subtypes glioblastoma multiforme (GBM) and non- glioblastoma 
multiforme (non-GBM) showed a difference due to demographics. 
Using age, sex and race, Dubrow and Darefsky studied the cases of 
GBM and non-GBM in the USA, utilising the SEER (Surveillance, 
Epidemiology and End Results program) data of 1992-2007. SEER 
provides online statistics of ‘new cases of’ and ‘deaths by’ specific 
cancers. In the case of Dubrow and Darefsky, the statistics for brain 
and nervous system cancers were used and in the study the authors 
state that a previous study showed race to have a major impact on 
brain tumours and the data they provided confirmed this. The authors 
confirmed that race played a key role in brain tumours by reviewing 
the SEER data, mentioned above. Dubrow and Darefsky concluded that 
non-hispanic whites numbered in over 20,000 new cases within the 
time period, whilst Native American new cases were approximating at 
100. Dubrow and Darefsky (2011) continued that race had significance 
in the glioma subtypes. This can be closely linked to the succeeding 
data, the most recent SEER data from 2008-2012. These data 
correlated with the results and conclusions put forward by   Dubrow 
and Darefsky and supported their initial hypothesis with regards to 
race having significance in glioma cases. Utilising the similar races, 
white and Native American, the number of new cases for a white 
individual was more than double that of a Native American. In males 
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8.4 per 100,000 people were of white ethnicity showing a new case of 
brain and/or nervous system cancer, on the other hand 3.7 per 
100,000 were Native American. A similar trend is present with females 
of both white and Native American ethnicity with 5.9 and 2.7 people 
respectively per 100,000 showing new cases (Seer.cancer.gov, 2017).  
These data are shown in table 1.2. These data have been created from 
the above data (SEER 2008-2012). 
Male Female 
White Native 
American 
White  Native 
American 
8.4 3.7 5.9 2.7 
Table 1.2- The table shows the data from SEER 2008-2012 for new cases of brain and/or nervous 
system cancer. The table shows the sex, race and then the number of new cases per 100,000 people 
in USA. 
 
This shows synergy with research by Crocetti et al. whom studied the 
case of glial and non-glial brain tumours across Europe in 2012. Their 
study indicated that different areas of Europe showed a different rate 
of occurrence and survival of brain tumours. The highest rates of brain 
tumours were in Western and Northern Europe i.e. UK, Iceland, and 
Norway. Central Europe showed intermediate rates of brain tumours. 
i.e. France, Germany and the Netherlands (see figure 1.7).  Lastly, the 
lowest rates were found in Eastern, and Southern Europe i.e. Poland, 
Czech Republic, Spain, Portugal, and Italy.  Coalescing all of this data on 
brain tumour incidences/ rates, it is obvious that race or racial 
background; a person’s ancestry, may have a larger impact on cancer, 
more specifically brain cancer, than previously thought. 
The schematic map in figure 1.7 shows Europe using Crocetti et al.’s 
research colouring the areas of high (red), intermediate (green) and 
low (blue) rates of brain tumours. 
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Figure 1. 7- A schematic map of Europe showing the glial tumour occurrence rates. The red 
indicates high rates in Northern and Western Europe. Green shows intermediate rates in Central 
Europe and blue shows low rates in Eastern and Southern Europe. 
The human population in terms of genetics is extremely closely 
related, independent of your racial/ ancestral background. Statistically 
all humans are an extended family tree with close and distant cousins 
living all over the planet. The original populations of humans were 
small communities that were extremely inbred (Marshall, 2013).  
These communities ultimately lead to the entirety of the current 
human population, which since has again been mixing and cross 
breeding over the millennia; forming a hyper inbred population. The 
simple fact that our genetics are so close to everyone else’s should 
result in disease genotype, phenotype, and disease rates being almost 
identical throughout humanity. The above data shows this to not be 
the case (Dubrow and Darefsky, 2011; Crocetti et al. 2012). 
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Reviewing the work by Crocetti et al. (2012), it is clear that even in 
Europe, an area of the world where almost all inhabitants can claim 
descent from King Charlemagne in the eight-century A.D., moreover 
brain cancer rates differ greatly from country to country (Ralph and 
Coop, 2013).  
In terms of genetics this is expected with a UK native genetically being 
a majority of western and northern European, with reference to 
England being conquered by the Anglo-Saxons, Vikings and French 
chronologically. These conquests have each added their genetics to the 
region, genetics where a majority has come from Western and 
Northern Europe, as shown in figure 1.5 in red. A sizable proportion of 
UK genetics would be central European, France and Germany, 
mentioned above. Lastly, very little of UK genetics would be southern 
and eastern European.  This collection of genetics in specific 
proportions may be the root of this distinct difference in brain tumour 
rates. A central European is intermediate because they have genetic 
drift (the passing of genetics with no specific selection) with both of 
the surrounding areas of high and low brain tumour rates. An example 
can be seen in any European royal family tree. Often were the 
marriages of royals in France, England and Scotland, and France, Spain 
and Italy. However, the marriages between Italian and British royal 
families were much rarer. These examples hold true for the 
populations of the countries mentioned, some inter-country marriages 
were more common than others. These simple occurrences may have 
all resulted in the brain tumour rates that are present today. Finally, a 
native of Eastern Europe, would have little western and northern 
European ancestry, but would contain some genetics from Asia, the 
middle east and perhaps even eastern Asia; China, India. 
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This supports the racial bias described by Dubrow and Darefsky 
(2011) with Asian brain tumour rates being much lower than 
European. Therefore, an eastern European native with their mixed 
genome of little western/northern European and a proportion of 
continental Asian genetics would appear in between both European 
and Asian rates of brain tumours (Dubrow and Darefsky, 2011). 
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1.7 The Debate of Race 
 
The close relation between humanity allows all races to be imagined as 
extended branches of the same family tree, and as such this is true. 
Figure 1.8 is a schematic taken from Campbell & Tishkoff, (2010) who 
did a review of the genetic diversity within Africa. The image shows a 
phylogenetic tree of human races, those whom are African and those 
who are not. 
 
Figure 1. 8– Figure taken from Campbell and Tishkoff 2010, showing that all non-africans come 
from a single line of individuals who migrated out (Shown as Phase III). Whilst the figure shows 
that sub-Saharan Africans have the highest amount of genetic variation. Note ‘Kya’ stands for kilo 
(thousand) years ago. 
Their study demonstrates the extreme closeness of all non-Africans, 
whilst indicating that Sub-Saharan Africans have the highest amount of 
genetic variation. This again proposes the question if the races are so 
closely related in terms of genetics, what genetic cause produces the 
difference in brain tumour rates? 
This question is parallel to the ‘race debate’ this is a term coined from 
the debate regarding whether races truly exist. This debate has seen 
positive and negative inputs from research over time, and more 
recently was the focal point of research by Quayshawn Spencer in 
36 
 
2015. Spencer wanted to deduce whether the small difference in 
genetics warranted the term ‘race’. The outcome of the research was 
mostly philosophical about the terminology of race. However, despite 
this Spencer confirmed his predecessors by stating that the human 
population has various clusters of individuals with specific genomic 
differences, termed genetic clusters. 
Avoiding the philosophy of race, biological evidences show that 
various clusters within humanity share closer genetics and similarly, 
have differences to those outside that specific cluster. These small 
differences within the genome of individuals are knows as single 
nucleotide polymorphisms (SNPs). These SNPs are single bases or 
small segments of a gene that differ to other individuals. It is important 
to note that whilst the two individuals’ genes would differ their 
genomes would both still encode the same protein, and both encode a 
functioning protein.  The differences of genes between races can be 
assimilated to the description above (‘The inheritance of Cancer’ 
section), a schematic showing the inherited mutations that increase 
the chances of cancer. The ‘silent’ acting differences between 
individuals are what give the human populations its’ variation and 
ultimately produce these clusters of humans; race (Spencer, 2015). 
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1.8 The Inheritance and Genetics of Brain Tumours 
 
With the human population being described above as an extended tree 
of the same family, familial/ germline mutations may then be 
prominent (Campbell and Tishkoff, 2010).  
In 2014, Bainbridge et al. researched germline mutations associated 
with glioma that specifically show a familial link, focusing on POT1. 
Germline mutations are heritable mutations that are transmitted from 
parent to offspring as mentioned above. Protection of telomeres 
protein 1 or POT1 protein is a member of the telomere shelterin 
complex that binds to both DNA and tripeptidyl peptidase 1 (TPP1). 
The role of these proteins is the activation of telomeres and protection 
of telomeres from DNA repair mechanisms that require chromosomal 
merging such as non-homologous end joining (NHEJ). A news article in 
the Lancet Oncology produced from this journal research written by 
Bagcchi (2015) reiterates how key this concept of familial linked 
genetic mutation and its’ research, may be. Bagcchi continues that the 
research by Bainbridge et al. found 2 POT1 mutants with an extremely 
strong association with familial inherited glioma. Both the journal and 
the news article stated that this genetic research would assist families 
and patients with these germline and familial mutations. The genetic 
‘passing down’ of DNA and the way the alleles are selected for to 
produce a phenotype is known as Mendelian genetics. A phenotype is 
the physical characteristics that appear or occur due to the genotype; 
genetic characteristics. Like the rest of the body, cancer inheritance is 
often allele linked and thus a question can be formed from this. If most 
alleles follow Mendelian genetics when being transmitted from parent 
to offspring, then it can be assumed that the alleles/ mutations specific 
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to cancer would also follow the pattern of Mendelian genetics, 
specifically natural selection. 
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1.9 Mendelian Genetics 
 
Mendelian genetics is a set of hereditary rules aptly named after its’ 
founder, Gregor Mendel (1822-1884).  Mendel studied pea plants, and 
how their flowers differed from parent to offspring. His experiments 
are shown below in a schematic of three generation of pea plant with 
two different version of the plant, one of white flowers and one of 
purple flowers (Mendel, 1866). 
 
Figure 1. 9– A schematic showing the experiments performed by Mendel on pea plants. Note the 
purple and white flower and the interbreeding of the 4 purple flowers to produce the 3:1 ratio of 
purple flowers: white flowers. 
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Figure 1.9 shows that when Mendel crossed the purple and white 
flowers, the only outcome was purple flowered offspring. From this 
Mendel self-pollinated those offspring and discovered that the second 
generation of the pea plants always grew in a ratio of three purple 
flowering plants to one white flowering plant (Mendel 1866). 
From this result, Mendel deduced that offspring inherit hereditary 
‘factors’ and that these factors can have two forms. These forms are 
inherited one from each parent and together they produce a particular 
single characteristic. Unbeknownst, Mendel had discovered genes and 
that those genes have multiple forms or alleles. 
This work has since been confirmed with the discovery of genes, and 
dominant and recessive alleles that Mendel himself coined. From this 
many studies have mapped inheritance patterns for various genes for 
example, the monogenic disease cystic fibrosis (Bowen and Hull, 
2015). 
Mendel published his work in 1866, which is now known to go 
perfectly alongside the 1859 work by Charles Darwin. Darwin 
proposed evolution by natural selection and dubbed two major 
factions of natural selection as fecundity and sexual selection.  Natural 
selection is fundamentally a difference in survival/reproductive rates 
due to a different phenotype. A different phenotype can be seen in the 
pea plants Mendel had studied during his research. Darwin discusses 
fecundity as reproductive success due to phenotype, and sexual 
selection as choice of mate based on their potential reproductive 
success (the number of offspring produced that survive into the next 
generation). 
Both mechanisms worked in synergy with Mendelian inheritance and 
thus became combined by Ronald Fisher during the first half of the 
twentieth century. Fisher had introduced the foundation for the 
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modern genetic theory of evolutionary biology and believed that 
natural selection was the major aspect of evolution with genetic drift 
playing a very minor role (Fisher, 1930). Genetic Drift is a change in 
the frequency of an allele and is due, in part to a lack of selective 
pressure, being completely due to random chance events favoring 
some individuals of a species over others. In 1968, Motoo Kimura 
introduced a sister branch within Mendelian genetics, promoting 
genetic drift as the process by which most variation is inherited. 
Kimura dubbed his theory as Neutral Selection, needing no selective 
pressure; due to the completely random nature of genetic drift. A 
branch in comparison to Mendelian genetics is Non-Mendelian 
Genetics, which includes various epigenetic patterns for inheritance 
including: genomic imprinting, X chromosome inactivation and various 
other expression patterns of alleles, RNA, and post-translational 
modifications. 
All Mendelian inheritance patterns follow the three law of Mendel 
shown below. 
Law of 
Segregation 
Law of 
Dominance 
Law of 
Independent 
Assortment 
Each gamete gains 
one allele 
One or more allele is 
dominant and is 
displayed as the 
dominant 
characteristic 
Genes are 
independently 
assorted during 
gamete production 
Table 1.3 – A table showing the three laws of Mendelian genetic/inheritance. Law of Segregation, 
Law of Dominance and Law of Independent Assortment. 
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These laws are adhered to by both branches of the Mendelian 
inheritance seen overleaf, but not by the Non-Mendelian inheritance of 
epigenetics mentioned above. Figure 1.10 is an image showing the 
branches of Mendelian inheritance that have been discussed above. 
 
Figure 1. 10- A schematic tree of Mendelian inheritance, showing the two branches of natural and 
neutral selection, proposed by Darwin (1859) and Kimura (1968) respectively. 
It has been concluded that approximately 50% of Mendelian 
phenotypes and conditions are unknown (Chong et al., 2015). 
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1.10 Epigenetics 
 
It has been apparent for some time that genetics is a major aspect of 
cancer development. However more recent studies are beginning to 
focus on genetic mutation perhaps not being the cause for various 
differences in the human population as no genes have yet been found 
for many conditions. Epigenetics is the study of heritable changes in 
gene expression (Lee, 2012). Epigenetics does not include changes in 
the DNA sequence or genome Lee continued, focusing his research on 
two epigenetic phenomena of X chromosome inactivation and genomic 
imprinting.  
X chromosome inactivation occurs when an X chromosome (xch) is 
silenced, for example in females, who carry two xch. Each cell of a 
female’s body will change the gene expression of xch to silence one, 
which occurs randomly in all cells; producing an xch mosaic affect 
throughout their body. The silencing of xch includes modifications of 
histone proteins and DNA methylation, the latter of which is the main 
form of epigenetic modifications of gene expression (Lee, 2012).  
Genomic imprinting is the expression of specific genes from the one 
un-silenced chromosome with silencing dependent on parent-of-
origin. The parent-of-origin has a crucial role in inheritance of disease 
states and thus cancer. Similar to X chromosome inactivation, DNA 
methylation (and therefore inherited methylation) and histone 
modifications are the main epigenetic changes in genomic imprinting; 
however unlike X chromosome inactivation, genomic imprinting 
occurs with all chromosomes and in both males and females. 
Dependent on the chromosome being from either the mother or father, 
the epigenetic change i.e. the change in gene expression, can cause a 
different phenotype despite no change of the genomic sequence 
44 
 
occurring, this again links to the familial inheritance of genetic 
information. These epigenetic changes occur early during embryonic 
development with abnormal imprinting being the route problem of 
many human diseases. More recent research is showing epigenetic 
changes to also control other aspects of phenotype that have no 
genomic evidence such as addiction, metabolism, weight and sexuality 
(György, 2017). The change of expression in one allele is commonly 
found in the genome and termed mono-allelic expression (Lee, 2012). 
Further to this, the change in expression of two alleles and their 
differences has been termed allele specific expression (ASE) (Lee, 
2012). ASE is largely affected by genetic polymorphism i.e. SNPs; 
which change the DNA base, but do not alter the amino acid, ultimately 
affecting the phenotype by manipulating the bodies ‘decision’ of which 
allele is used, changing expression (Lee, 2012). ASE opens studies up 
by allowing the research into the gene expression differences between 
different people whom have slight differences in their genotype. This 
links to the study of racial bias toward cancer with races differing only 
slightly in genetics, SNPs. Methylation of DNA, as mentioned, is the 
main modification identified in epigenetics and Lee (2012) mentions 
how allele specific methylation can be transmitted through the germ-
line and hence through generations of descendants. This highlights the 
importance that the inheritance pattern of cancer may have. Further to 
this, it shows that epigenetics may also be subject to Mendelian 
genetics much like the genomic mutations discussed. 
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1.11 Neurofibromatosis – Predisposition to Glioma 
 
Glioma has been discussed in chapter 1.4 as the major group of brain 
tumours, cancers of the glial cells. Various types have been shown and 
multiple sub-types from these. However, many tumours begin 
somewhere else and often are dubbed as a different disease. In a 
chapter of ‘Glioma- Recent results in cancer research’, by von Deimling 
(2009) discusses the importance of understanding hereditary tumour 
syndromes and their predisposition to gliomas. The main 
predispositions they discuss are neurofibromatosis type 1 (NF1) and 2 
(NF2). Type 1 is known as the peripheral form, whereas type 2 is the 
central form. Type 2 involves tumour growth along the spine, brain 
stem and predisposes patients to develop brain tumour growths 
specifically in glial tissue and hence a predisposition to gliomas.  
The chapter continues discussing the overlap of molecular 
pathogenesis between glioma and both types of neurofibromatosis 
amongst other predispositions and finds a likeness to the disruption to 
the likes of Ras and its downstream pathway. The authors conclude 
that gaining a greater understanding into hereditary predispositions of 
brain tumours will aid a better understanding of their formation and 
their inheritance (von Deimling, 2009). 
NF2 is an inheritable disorder first described in the early 20th century, 
having since been greatly researched. Lloyd and Evans (2013) in the 
Handbook of Clinical Neurology, stated that 50-60% of NF2 cases are 
de novo with no previous familial link, however of these, 70% carry 
the mutated NF2 gene in all cells meaning that the individual can now 
transmit the disorder to an offspring, creating a familial link. The 
remaining 30% of de novo cases gain a mutant cell line and a non-
mutant cell line producing unilateral and bilateral forms both having a 
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chance of transmitting the disease down the germ line; again, creating 
a familial link. Lloyd and Evans (2013) described the variation in NF2 
phenotype including the age of disease onset, speed of the disease 
progression and the extent of the disease; with a family’s phenotype 
often showing a similar severity. Therefore, if a family shows a similar 
phenotype, it can be hypothesized that the family’s genotype would be 
similar. This tumorous disorder shows many characteristics to its’ 
potential successor; glioma, in that both have a strong familial link and 
similar phenotypes. The change in phenotype and its variation, despite 
a similar and often linked genotype again may show evidence that 
epigenetics may have a key role in cancer inheritance and more so in 
NF2, and its’ inheritance. The disorder NF2 is associated with a change 
in the protein Merlin, encoded by the NF2 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
1.12 Merlin Protein Biology 
1.12.1 Molecular Biology 
 
Merlin stands for Moesin-Ezrin-Radixin-Like Protein and is part of the 
ERM (Ezrin, Radixin and Moesin) family of protein (Sun et al, 2002). 
Merlin was named so due to the similarity it has to Ezrin, Radixin and 
Moesin. Merlin is placed in its family mainly due to the FERM domain 
all family members have. The FERM domain is the module of the 
proteins that all of the family share; the domain allows all family 
members to bind to the cell membrane. FERM stands for Band 4.1 
Ezrin Radixin Moesin homology domain (Sun et al, 2002).  The ERM 
family is highly conserved throughout evolution due to the association 
and activity within the cell membrane and its interface to the 
cytoskeleton; often having roles in membrane localisation of proteins. 
Other roles of this protein family are the processing of extracellular 
signals and downstream signaling within cells, as described by Morrow 
and Shevde (2012) and Cooper and Giancotti (2014). All members of 
the family have a FERM domain, allowing ERM proteins to interact 
with cell membrane proteins. The merlin protein in humans is 68kDa 
with 17 exons comprising of 595 amino acids. The three domains are 
the tri-lobed FERM domain at the amino terminal, an alpha-helical 
domain, often referred to as a coil-coil region, and the carboxyl 
terminal domain. Cooper and Giancotti (2014) explain that Merlin 
shares much homology to other ERM proteins and it is currently 
assumed that they share a similar activity to suppress mitogenic 
signaling at the cell cortex to mediate contact inhibition. Despite this 
assumption, no evidence has yet confirmed merlin’s similarity to ERM 
proteins; however, ERM proteins are shown to have roles as a tumour 
suppressor (TS) again implicating a homology to merlin. Lloyd and 
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Evans (2013) describe that there are 2 isoforms of Merlin; one is an 
active, dephosphorylated and closed form, and the other is an inactive, 
phosphorylated and thus open form. This is now thought to be correct 
as further research, and the review by Cooper and Giancotti (2014) 
corresponds with the concept described by Lloyd and Evans (2013). 
The image figure 1.11 shows merlin’s similarity to the ERM family 
proteins, however the image also shows that the FERM domain is 
present in other proteins that are not in the same family and share no 
other homology to the ERM family other than the FERM domain (Sun 
et al, 2002). 
 
Figure 1. 11- Taken from Sun et al, 2002 shows the similarity that merlin has to other ERM family 
proteins 
The image figure 1.12 shows merlin’s two forms (active and inactive) 
and their speculated shape and conformation. Section C of the image 
below shows known molecules that merlin binds to, these include 
structural molecules and its’ fellow proteins. 
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Figure 1. 12- Taken from Sun et al, 2002 shows the active and inactive forms of merlin and known 
molecules that merlin interacts with. 
1.12.2 Activity of Merlin 
1.12.2.1 General activity of Merlin in Humans and D. melanogaster 
 
Despite the expected homology to other ERM proteins the true details 
of merlins’ role is unknown requiring further study (Lloyd and Evans, 
2012; Cooper and Giancotti, 2014). However, research shows links to 
many cancer-associated pathways at the cell membrane and within the 
nucleus. Morrow and Shevde (2012) reviewed merlin’s protein 
stability as a tumor supressor stating that the main aspect that has 
been researched was the loss of function of merlin which results in the 
over proliferation of nerve cells. The three mechanisms of tumour 
suppression that merlin utilises are decreases in proliferation, 
increases in apoptosis and the disputed contact-dependent growth 
inhibition (CDGI). Cooper and Giancotti (2014) explain that merlin was 
suspected to utilise contact inhibition due to its homology to the ERM 
family. Morrow and Shevde (2012) in their review discuss merlin’s 
ability to disrupt Ras and Rac signalling pathways, which can lead to 
50 
 
contact-dependant growth inhibition. They next focus on the homology 
between humans and D. melanogaster in terms of the merlin protein 
and how merlin’s ability to decrease proliferation and induce 
apoptosis is highly conserved in both species. This highlights not only 
the similarity between merlin and its associated mechanisms and 
pathways in both D. melanogaster and humans, but the key role merlin 
has in terms of proliferation and apoptotic regulation in both 
organisms. Recent research into merlin has also shown new pathways 
and links to its role in decreasing or stopping downstream 
proliferation signals. (Yu and Guan, 2013) One of the more recent 
pathways researched is the Hippo pathway, present and highly 
homologous in both humans and D. melanogaster (Yu and Guan, 2013), 
in which the open state of merlin is now considered active in terms of 
tumor suppressor activity and the control of contact inhibition. In the 
hippo pathway, merlin activates Yap/Taz in mammals and the 
homologue in D. melanogaster, Yorkie. This reveals a role in regulating 
organ size, stem cell behaviour and cell proliferation. Morrow and 
Shevde (2012) state that much research has focused on merlin 
mutations in the genome, however epigenetics and protein regulation 
may in fact be the principle cause of NF2 and the associated brain 
cancers of glioma and meningioma, amongst others (Morrow and 
Shevde, 2012). The review continues stating that multiple mechanisms 
of genomic change are the likely cause of merlin inactivation; this again 
supports both the genomic change and epigenetic change that may 
influence the inheritance and therefore the activity of merlin. DNA 
methylation is likely to play the largest role in the epigenetics of 
merlin, however other studies have shown there to be some 
contradiction within research showing a decreased methylation in 
merlin inactivation. Morrow and Shevde (2012) highlight the need for 
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more research into the genetics of merlin, not only the inherited 
mutation, but also the epigenetics of merlin. The authors finish by 
stating that the expression level of merlin may have implications to its 
inactivation, however this again requires further research due to lack 
of conclusive evidence (Morrow and Shevde, 2012). 
Figure 1.13 shows a simple schematic overview of merlin’s activity 
throughout the cell. At the cell membrane, merlin interacts with 
integrins, RTK’s, and catenin and cadherin that allows the regulation of 
many cancer aspects and the hallmarks previously mentioned. Merlin 
has a second major role within the nucleus where it interacts with an 
E3 ligase, regulating further genomic aspects of cancer (Utermark, 
Kaempchen, and Hanemann, 2003; Rong et al., 2004; Higa et al., 2006; 
Mitra and Schlaepfer, 2006; Curto and McClatchey, 2007; Curto et al., 
2007; Lee and Zhou, 2007; Lallemand et al., 2008; Pan, Weinman, and 
Le Dai, 2008; Dummler et al., 2009; Streuli and Akhtar, 2009; Li et al., 
2010; Soung, Clifford, and Chung, 2010; Li and Giancotti, 2010; Read et 
al., 2011; Li et al., 2012; Zhou and Hanemann, 2012). 
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Figure 1. 13- Merlin’s role at both the membrane and the nucleus. At the membrane merlin 
regulates a number of proteins that are involved in various oncogenic pathways (See text for details 
of references, such as page 51). 
1.12.2.2 Merlin activity at the membrane 
 
Merlin has various roles throughout the cell acting primarily at the 
membrane and within the nucleus. Merlin acts as a control, a regulator, 
and forms numerous complexes during its’ role as a multi-suppressor 
(Zhou and Hanemann, 2012). Merlin has some control over integrins, 
the cell-cell bridges, with a loss of merlin producing an increase in 
integrins and in turn increase cell adhesion (Utermark et. al, 2003). 
Alterations in cell adhesion are associated with cancer metastasis. 
Once activated, integrins undergo various interactions that begin 
downstream affects and pathways. For instance, integrins recruit 
signalling proteins Rac1 and Cdc42, whom in turn interact. From this 
Pak is activated (Dummler et al., 2009), which creates a feedback loop 
by phosphorylating merlin at serine 518, producing the inactive form 
(Rong et al., 2004). Secondly Pak activates some major cellular 
pathways associated with cancer; ERK and JNK, both which promote 
the regulation of cell survival, apoptosis, and tumourigenesis. Integrins 
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also regulate: Fak and the associated src proteins (Mitra and 
Schlaepfer, 2006), which function upstream of more cancer associated 
pathways; Raf and PI3K which promote cell survival, proliferation and 
migration. Merlin has a second regulatory control of PI3K, by actively 
inhibiting it. Merlin inhibits PI3K by competing with PI3K enhancer 
long form (PIKE-L) (Rong et al., 2004). Therefore, by inhibiting PI3K, 
merlin can regulate cell proliferation and survival. Integrins have been 
shown to work with regulatory tyrosine kinases (RTK’s) in recent 
studies (Streuli and Akhtar, 2009; Soung et al., 2010). The synergy 
between integrins and RTK’s, including VEGFR, IGF1R, ErB receptors 
and PDGFR mediates signalling pathways. Merlin has control over both 
RTK’s and Integrins. Merlin’s process of regulation of RTK’s is 
unknown however it has been suggested that it regulates endocytotic 
trafficking of RTK’s (Lallemand et al., 2008). Merlin forms a complex 
with many proteins, for example, the complex with PDGFR through Na+ 
H+ exchange regulatory cofactor (NHERF), a complex which was 
suggested by Pan et al. (2008) and confirmed by Lallemand et al. (Pan, 
Weinman, and Le Dai, 2008; Lallemand et al., 2008). Na+ H+ exchange 
regulatory cofactor has recently been described as a potential new 
cancer marker due to its gradual increase and cofactor role in many 
cancer types, including glioma (Dell’Endice et al., 2014). Lastly 
integrins have been shown to activate mTORC1, a complex of mTOR. 
mTOR pathway regulates protein synthesis, and due to this, many 
cancer-associated affects arise from this including cell proliferation 
and survival. Cadherins and Catenins are proteins that allow cell-cell 
adhesion, anchoring cells to one another. Merlin has been shown to 
form complexes with the catenin and cadherin complex. Other studies 
have shown merlin not only forms complexes with E/N-cadherin and 
B-catenin, but through contact-dependent inhibition of proliferation 
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may control all downstream affects by regulating catenins-cadherin 
complexes, integrins and RTK’s (Curto and McClatchey, 2007; Curto et 
al., 2007). By regulating downstream pathways, merlin may ultimately 
control the development of the major hallmarks of cancer specifically 
proliferation, cell survival, apoptosis and metastasis (Hanahan and 
Weinberg, 2000). 
1.12.2.3 Merlin activity within the nucleus 
In its dephosphorylated/closed form, merlin enters the nucleus due to 
a strong affinity to DNA damage-binding protein 1 (DDB1) and, DDB1 
and CUL4 associated factor homolog 1 (DCAF1) (Lee and Zhou, 2007; 
Li and Giancotti, 2010; Li et al., 2012). DCAF1 is a substrate receptor 
for Cullin-ring ligase 4 (CRL4), E3 ligase. Merlin only has said affinity 
when it is the wild-type allele. Knock-out or null model organisms for 
merlin have shown no affinity to enter the nucleus (Lee and Zhou, 
2007). It is also unlikely that mutant merlin would have the same 
affinity if any at all. The CRL4 complex was shown to have many roles 
in cell cycle regulation, histone methylation and genomic stability 
(Higa et al., 2006). By binding to DCAF1, merlin can inhibit DCAF1 
binding to CRL4 and therefore inhibit CRL4 activity. From this merlin 
can broadly regulate gene expression by inhibiting CRL4 (Li et al., 
2010).  By entering the nucleus, merlin ultimately inhibits CRL4. In 
merlin deficient tumours, CRL4 must have a role in tumourigenesis.  A 
change in merlin or DCAF1 levels alters the production of integrins and 
RTK by altering protein degradation (Li et al., 2010). This allows the 
hypothesis that merlin can create its’ own feedback loop. By entering 
the nucleus merlin interacts with DCAF1 and CRL4, altering the 
production of integrins and RTKs. Merlin, as aforementioned, interacts 
with these and by affecting their production affects its’ own activity 
with integrins and RTKs at the membrane. 
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1.12.2.4 Dysfunction of Merlin 
 
A dysfunctional or lack of merlin is known to cause NF2, merlin is 
however dysfunctional in many cancer forms and the reason for this is 
stated above.  Merlin produces its’ own feedback loop by regulating 
CRL4 within the cell’s nucleus. This in turn regulates many of the 
proteins in production, majority being RTKs and integrins. Therefore, a 
change or loss of merlin alters the regulation of integrins and RTKs by 
altering their production. Secondly to this, merlin has a variety of 
interactions at the cell membrane with integrins and RTKs, and a 
change in the production of these changes merlin’s ability to interact. 
However, if a cell is lacking merlin, or it is dysfunctional, the 
interaction that would normally occur at the membrane would not 
occur or would not produce the same outcome. It is therefore 
important for merlin to be present and more importantly, functional 
(Zhou and Hanemann, 2012). 
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1.13 Drosophila melanogaster – Model Organism 
 
With a simple eukaryotic genome; Drosophila melanogaster (D. 
melanogaster) have become a common model organism, being utilised 
in many areas of scientific research. The genome consists of 4 
chromosomal pairs with homology to human disease states. D. 
melanogaster live for approximately a month, from egg through to 
adult. After hatching from an egg, D. melanogaster feed as a larva. This 
larva grows through three stages of larval growth called instars; each 
instar increasing the larva’s size. The larva then pupate before they 
eclose as adult D. melanogaster. The process from egg to adult D. 
melanogaster takes approximately 14 days.  
Figure 1.14 shows D. melanogaster as seen down the lens of a 
dissecting microscope at x10 magnification. Adult flies can be seen 
surrounding several pupa cases. The blue substance is the media in 
which they grow and feed. Note that these are Wild-Type D. 
melanogaster of both sexes. 
 
Figure 1. 14– Wild-Type D. melanogaster shown using  x10 magnification 
D. melanogaster 
 
 
Pupa Case 
 
Quick Mix 
Media 
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D. melanogaster, being insects, means their development is impacted 
by temperature, as temperature increase, so does D. melanogaster 
development, shortening the time from larval to adult D. melanogaster 
growth. The opposite is said for cold temperature, lengthening the D. 
melanogaster development (Oliphant et al., 2014). 
For many years the use of D. melanogaster as a model organism 
specifically in cancer has been researched because of their genetic 
homology to the human genome.  This has been the main advantage for 
use of D. melanogaster. Many of the proteins seen in human cancers 
and those associated with human cancers are highly conserved in D. 
melanogaster as stated by Polesello et al. (2011) in ‘modelling cancers 
in D. melanogaster’ an article regarding animal models for human 
disease. The chapter continues discussing the use of D. melanogaster 
and their often-identical oncogenic pathways to a mammalian model, 
coupled with many homologous proteins, which control and suppress 
said pathways. This is supported by Read et al. (2009) who explain the 
homology of glial cells and thus the tumours associated with them in 
relation to both D. melanogaster and mammals. From this, a great 
homology between D. melanogaster and mammalian glial tissue and 
hence glioma can be seen; D. melanogaster can be utilised as a practical 
model organism for glioma study. Read et al. discussed the Ras and 
PI3K pathways in D. melanogaster, showing a great similarity to 
humans (Read et al., 2009). Read (2011) further researched D. 
melanogaster, studying pathways for the development of glioma, 
confirming their evident use as a model organism for modeling GBM 
and non-GBM glioma subtypes. D. melanogaster have been used for 
genetic experiments for over a century because of the easy breeding, 
fast life cycle and simple eukaryotic genome. The knowledge gained 
from D. melanogaster experiments has shaped the molecular world 
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today, with genetics, evolution and inheritance playing major roles. 
However, it is key to note that they do have various advantages, the 
major factor being the temperature dependency, not seen in 
mammalian models. Similarly to mammal models is the simple fact 
that D. melanogaster are not human and therefore despite a similar 
genome it is not an exact replica.  
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1.14 Merlin in D. melanogaster and Humans 
 
D. melanogaster and humans both have a similar merlin, D. 
melanogaster merlin dubbed ‘dmer’ (McCartney, et al., 1996). 
Found on the X Chromosome positioned 19,689,697 to 19,693,500. 
Dmer is bigger than its’ human counterpart being 74kDa, whereas 
human merlin is 69kDa. However, both still appear to perform a 
similar role in studies that have been done. One such study used 
human merlin to rescue merlin-lethal D. melanogaster with success; 
this shows the highly conserved nature of merlin in both organisms 
(LaJeunesse, et al., 1998; Golovnina, et al., 2005). Despite this 
similarity, no alleles of merlin have been researched in humans, 
opposing to this, many alleles have been researched in D. melanogaster 
such as Mer 3 and Mer 4 amongst many others. 
Dmer has been shown to function upstream and regulate regulatory 
proteins for cell growth and division. Dmer itself showing the function 
of cell survival, and cell proliferation regulation. With a loss of Dmer 
showing a compromise to normal apoptosis functioning and 
spermatogenesis (Pellock et al., 2006; Dorogova et al, 2008; 
Bolobolova et al., 2011).  
This shows much similarity to figure 1.15, showing the function of 
merlin in human studies with reference to cell-cycle, cell proliferation 
and apoptosis (Figure 1.15). 
Studies have focused on the hippo pathway, a pathway mentioned 
above in human models. The image below (Figure 1.15) shows the 
pathway in both D. melanogaster and humans parallel (Zhao et al, 
2011). 
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Figure 1. 15- Taken from Zhao et al, 2011 an image showing the Hippo pathway in both mammals 
and drosophila, showing the similarity between the two and the homologous proteins (Mer). 
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The image is evidently similar; both models look almost exact, with 
merlin playing the same roles in both. Despite this similarity, little 
research has investigated the other roles of merlin, aforementioned in 
humans, such as the role in the nucleus or interactions with integrins 
and RTKs. 
1.15 Introduction to the Methodology 
 
Given that each race of humans differs mostly by SNPs, it is key that the 
D. melanogaster model has groups that differ also by a single point 
mutation. The wild type D. melanogaster became the control ‘normal’ 
merlin allele. The two remaining D. melanogaster populations had 
different variants of merlin. The variants are both a single point 
mutation, a substitution of one DNA base for another. No studies have 
mapped the merlin alleles within the human population, however due 
to our close relatedness as a species a single point mutation seems the 
most applicable variation that would be present. 
D. melanogaster with different versions of merlin gene represents the 
different races of the human population. Therefore, by isolative 
reproduction, a model of human race evolution has been produced. 
This is shown represented by the three distinct populations of D. 
melanogaster with their allele/variant of merlin. From this, one can 
then assimilate the recent mixing of human races and discover the 
inheritance pattern of merlin in D. melanogaster by allowing the 
different populations to mix and breed.  These mapping strategies, 
called linkage mapping have been shown to be useful techniques. 
Linkage mapping is mapping a particular locus across generations and 
progeny and has been shown to be ‘fruitful’ in many organisms when 
studying gene variants that contribute to a phenotypic variation 
(Schacherer, 2016).  
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The three variants of D. melanogaster merlin (Mer) were Mer3, Mer4 
and Wild type (Wt) Mer. Mer3 and Mer4 produce a different phenotype 
with increased mortality and would thus act as ‘recessive’ traits in 
comparison to the wild type variant. Mutant alleles are a loss of 
function. A loss of function causes over proliferation, often seen in a 
change of phenotype, specifically the head and eyes, also throughout 
the body of the D. melanogaster. This leads to major physical 
deformities and an increased mortality. The three merlin variants were 
chosen mainly due to their viability, many other merlin mutants did 
not produce offspring and those that did had sterile or undeveloped 
offspring. Both Mer 3 and Mer 4 have been used in various studies, 
with authors often claiming various classes of phenotype from viable 
and increased cell number, through to sterile and lethal. An example is 
Mer 3 being claimed as viable in 1998, but a decade later in 2008 the 
male Mer 3 are sterile (LaJeunesse, et al., 1998; Dorogova et al., 2008). 
This would not be viable in this type of methodology, where 
inheritance pattern is a main concept, therefore non-viable and non-
breeding offspring would be unsuitable. Both mer 3 and 4 are point 
mutations in the promoter region. This is similar to humans who too 
have a point mutation of merlin to cause the NF2 phenotype. Mer 3 is a 
missense mutation (Met177 – Ile) and Mer 4 is a nonsense mutation 
(Gln170 – Stop Codon) (Dorogova et al., 2008). 
Multiple populations of all variants will be required to allow for 
mortality of D. melanogaster and to ensure genetic variation is 
withheld and not lost due to excessive interbreeding. The number 
within a population can vary from 15-50 to begin with and as they 
continue breeding a population can reach up to 500 individuals. It is 
therefore the number of individuals that is particular instead of the 
population numbers. This cannot be predicted due to the 
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unpredictable breeding of D. melanogaster. Mutant merlin in humans is 
unstable, thus producing the cancerous phenotype. This instability is 
mirrored in D. melanogaster and is seen as increased mortality rates. 
 
 
1.16 Working Hypothesis 
 
The working hypothesis states that merlin will produce an inheritance 
pattern dictated by Mendelian genetics (either by natural or neutral 
selection), and/or provide probability of epigenetic manipulation.  
 
1.16.1 Main Aim 
Identify if merlin follows Mendelian genetics in regards to inheritance 
and/or that epigenetic manipulation may be apparent in the proteins 
inheritance 
 
1.16.2 Specific Aims 
The first aim is to deduce whether proteins such as merlin, which have 
major effects on cells and are encoded by a single gene (Monogenic), 
are inherited in a specific pattern. A pattern dictated by Mendelian 
genetics, either dominant or recessive by natural selection or by 
genetic drift/ neutral selection. 
Secondly, the research aims to discover whether many proteins like 
merlin have a genetic dependency, or in fact whether epigenetics plays 
any role in their dysfunction and therefore cancerous phenotype 
produced. 
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2.1 Materials 
2.1.1 Flies 
Wild-Type D. melanogaster Melanogaster from Blades Biological Ltd 
Mer 3 D. melanogaster Melanogaster from Bloomington D. 
melanogaster Stock Center at Indiana University (9103) 
Mer4 D. melanogaster Melanogaster from Bloomington D. melanogaster 
Stock Center at Indiana University (9104) 
2.1.2 Fluids, Chemicals and Reagents 
D. melanogaster Quick Mix Media from Blades Biological Ltd 
Flynap Kit from Blades Biological Ltd 
Distilled H2O 
2.1.3 Equipment 
D. melanogaster Vial 
Plastic ‘ladder’ 
Paint Brush 
Petri Dish 
Foam Bung 
Gilson Pipette 
Eppendorf Tubes 
PCR Tubes 
Water Bath 
Vortex 
Microcentrifuge 
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2.2 Method – D. melanogaster Breeding 
 
Three populations of D. melanogaster were set up initially and crossed 
throughout the experiment. Each population required a plastic vial 
with a bung. In this vial 5 g of Quick Mix medium and 15 ml of distilled 
water create a blue medium base for the vial, in which the larva live. A 
small amount of yeast was added atop the medium, providing the D. 
melanogaster with food. A plastic mesh ladder was placed on top of the 
medium (curved into a ‘U’ shape), providing a support for the D. 
melanogaster pupa. The protocol for this is provided on the packaging 
of the Quick Mix medium. 
The first stage of the experiment was establishing the three distinct D. 
melanogaster populations. This is shown in figure 2.1 below. 
 
Figure 2.1- Diagram showing the three variants of Mer, each established separately from each other 
in individual vials. 
The D. melanogaster populations, once established, were crossed. 
These new mixed populations interbreed, producing a hybrid 
generation of offspring. Figure 2.2 shows the primary crossing of two 
of the three variants. 
Wild-Type Mer Mer 3 Mer 4 
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Figure 2.2- Diagram showing the crossing of two Mer variants, Wild-Type Mer and Mer 3. With 
their offspring being a hybrid population (Wild-Type Mer x Mer 3). 
This hybrid population was then established and allowed to reproduce 
to the next generation of D. melanogaster. These offspring of the hybrid 
D. melanogaster were bred for a further generation to fix the genes 
within the population. The remaining Mer mutation variant was 
(A) Wild-Type Mer 
(B) Mer 3 
(C) Wild-Type Mer 
x 
Mer 3 
68 
 
crossed with the Wild-Type, producing two hybrid populations and 
this again was allowed to continue breeding to fix the genes within this 
population. This can be illustrated by figure 2.4, which shows the 
populations breeding for a further generation to which genes became 
fixed within the population. The figure (2.4) also shows those 
population that were mixed with an additional population. 
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Figure 2.3- Diagram showing the crossing of two Mer variants, Wild-Type Mer and Mer 4. With 
their offspring being a hybrid population (Wild-Type Mer x Mer 4). 
(A) Wild-Type 
Mer (B) Mer 4 
(C) Wild-Type 
Mer 
x 
Mer 4 
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As stated above the two hybrid populations were in turn allowed to 
breed, fixing the genes within the population; producing generation 
two of each individual hybrid population. Individuals from both hybrid 
population were then manipulated producing a ‘double hybrid’ 
population with all three merlin variants (Wild-Type, Mer 3 and Mer 4) 
as their ancestral populations. Lastly the stock population of Wild-
Type D. melanogaster, was used as a control descendant with no merlin 
mutants present in the lineage at any point. The sample of this 
population was taken at approximately generation ten. 
The schematic of the population family tree below shows the 
populations relatedness to one another. It is important to note that 
despite the simplistic schematic, care was taken to ensure the 
populations kept natural genetic drift and variation, and such multiple 
sub-populations of each stated population were kept ensuring little 
interbreeding occurred. 
 
Figure 2.4 – A schematic family tree of the populations researched within this study. The tree 
shows the relationships between the various populations 
The survival rate and mortality rate were calculated for all populations 
to determine the viability of the three Mer variants. These rates and 
the phenotypic ratios of potential offspring from the possible 
combination of parents were also calculated from this. 
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3.1 Qualitative Results – D. melanogaster Breeding 
 
D. melanogaster breeding can be a simple, productive method due to 
their quick succession in population size and reproductive capabilities. 
Despite this, D. melanogaster with the mutations have been more 
challenging to breed. 
Breeding the D. melanogaster with merlin variant Mer 3 and Mer 4 
proved difficult as many of the D. melanogaster would die as young/ 
larva or die during pupation. The outcome of this was that fewer 
numbers of these mutant D. melanogaster did not survive to adult and 
therefore many did not reach the stage where reproduction was 
possible. Therefore, multiple populations of merlin mutant D. 
melanogaster were required to allow this method to succeed. The D. 
melanogaster mutants Mer 3 and Mer 4 had already been selected by 
myself from a vast array of merlin mutant D. melanogaster due to their 
ability to breed. Many D. melanogaster with mutations in merlin 
showcased an inability to breed due to merlin’s activity in gamete 
production. Despite these apparent issues, a sustainable population of 
both merlin mutants; Mer 3 and Mer 4, was produced and could be 
manipulated per this methodology. 
Those Mer 3 and Mer 4 mutant D. melanogaster that did survive were 
not as easy to maintain as their wild-type counterparts, resulting in the 
high mortality mentioned. This high mortality continued down the 
generations with the offspring population of Mer 3/ Wild-Type hybrids 
and Mer4 /Wild-Type hybrids, often dying early in development. Due 
to this many populations of D. melanogaster perished before 
experimentation was able to take place. The main factor to consider in 
the maintenance of the D. melanogaster was and is temperature 
control. As with all insects, D. melanogaster require a near constant 
temperature to breed, however increased temperature can in turn 
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increase their breeding capabilities and speed up their embryonic and 
metamorphic development. The opposite, however can be said for D. 
melanogaster populations maintained in decreased temperature. This 
decreased temperature in turn decreases embryonic and metamorphic 
development, and breeding capabilities. 
Once populations were established, and hybrids themselves had 
survived, the rate of mortality drastically decreased to that which can 
be considered normal levels, those levels of natural mortality seen by a 
Wild-Type population. The images below show the initial population’s 
phenotype and the outcome that becomes individuals with a mutant 
merlin allele. Wild-Type have an unaffected merlin gene/protein and 
so have normal growth and reproduction (see figure 3.1). Mer 3 D. 
melanogaster have less coloration on their abdomen and no coloration 
in their eyes, this is apparent when compared the red eye pigment of 
the Wild-Types. The Mer 4 D. melanogaster similarly to the Mer 3, have 
the lighter body coloration and again have a phenotype seen by their 
eyes with the Mer 4 individuals having ‘slit eyes’ with only a small 
section of pigmentation. It is also important to note the lack of 
uniformity in Mer 4 D. melanogaster sizes, the two individuals shown 
in figure 3.2 are two individuals of the same population and the size is 
not a result of sexual dimorphism, just a characteristic of the mutant 
merlin phenotype. 
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Figure 3.1 – Wild-Type D. melanogaster showing various body colours, normal levels of growth and 
replication and red pigment in the eye. Sizes are uniform (x10 magnification) 
 
 
Figure 3.2 – Mer 3 D. melanogaster showing a single colouration on their body and lack of red 
pigment in their eyes. Sizes are uniform (x10 magnification) 
 
 
Wild-Type D. melanogaster 
Mer 3 D. melanogaster 
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Figure 3.3 - Mer 4 D. melanogaster showing a single colouration on their body and lack of red 
pigment in their eyes. The eyes are only pigmented in a small area of the eye producing ‘slit eyes’ 
Sizes are not uniform (x10 magnification). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mer 4 D. melanogaster 
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3.2 Quantitative Results  
3.2.1 Mortality Rates and Survival Rates 
 
The D. melanogaster that survived breeding as mentioned above were 
crossed to produce hybrid populations of Mer 3 and Wild-Type, and 
Mer 4 and Wild-Type. These were then bred using the breeding 
method outlined in Chapter 2. Note the control population was the 
Wild-Type population. 
D. melanogaster  
Population 
Survival rate of D. 
melanogaster  
(Percentage/%) 
Mortality rate of D. 
melanogaster   
(Percentage/%) 
Wild-Type 97% 3% 
Mer 3 34% 66% 
Mer 4 27% 73% 
Wild-Type x Mer 3 55% 45% 
Wild-Type x Mer 4 56% 44% 
Mer 3 x Mer 4 0% 100% 
Wild-Type x Mer 3 
Generation 2 
61% 
39% 
Wild-Type x Mer 4 
Generation 2 
81% 
19% 
(Wild-Type x Mer 3) 
x (Wild-Type x Mer 
4) 
 
87% 
 
 
13% 
Wild-Type 
Descendant 
93% 
7% 
 
Table 3.1 – A table showing the survival rates and mortality rates for each population of D. 
melanogaster. 
 
Table 3.1 shows the survival rate and mortality rate of the various 
populations of D. melanogaster. The mortality rate is the number of 
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individuals that died divided by the number of individuals that were 
produced/eclose, multiplied by 100. This is seen in the equation below. 
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 𝑡ℎ𝑎𝑡 𝑑𝑖𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 𝑡ℎ𝑎𝑡 𝑤𝑒𝑟𝑒 𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑑/𝑒𝑐𝑙𝑜𝑠𝑒
 𝑥 100  
 
Once the mortality rate was calculated, the survival rate could also be 
calculated as this was 100% minus the mortality rate. Table 3.1 shows 
that the highest survival rate and therefore the lowest mortality rate 
was seen in the wild-type D. melanogaster this only decreased slightly 
to 93% in their descendants, generations later. In contrast to this, the 
lowest survival rate and therefore highest mortality rate was seen in 
the Mer 3 and Mer 4 population where all offspring died/ never 
reached adulthood. 
The next highest mortality rates were seen in the Mer 3 and Mer 4 
populations with mortality at 66% and 73% respectively. The hybrid 
populations of wild-type with Mer 3 and Mer 4 showed an increased 
survival and therefore lower mortality rate than the Mer 3 and Mer 4 
populations. The rate however, was still resulting in 44% and 45% of 
D. melanogaster dying.  
The wild-type/Mer 3 hybrid population showed a small decrease in 
mortality rate in the second generation, with the rate being 39%. On 
the other hand, the hybrid population of wild-type/Mer 4 D. 
melanogaster showed a more drastic decrease in mortality rate in the 
second generation, with the mortality rate decreasing to 19%. 
Lastly the population that contained all three Mer variants had a 
mortality rate of 13% which was approaching the rates seen in the 
wild-type populations of D. melanogaster. 
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3.2.2 Phenotypic Ratios 
 
In the Wild-Type population, only wild-type individuals are available 
and therefore the parents of all offspring are wild-type D. melanogaster   
 
Parent Phenotype Phenotypic ratio of offspring expected 
Wild-Type x Wild-Type 1:0 of Wild-Type: Other variants 
Or 
100% of offspring would be Wild-Type. 
Table 3.2 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of wild-type D. melanogaster. 
 
In the hybrid population of wild-type D. melanogaster and Mer 3 D. 
melanogaster there would be three possible parental combination as 
shown in the table below, each with a specific phenotypic ratio. 
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Parent Phenotype Phenotypic ratio of offspring expected 
Wild-Type x Wild-Type 1:0 of Wild-Type: Other variants 
Or 
100% of offspring would be Wild-Type. 
Wild-Type x Mer 3 1:0 of Wild-Type/Mer 3 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Wild-Type/Mer 3. 
Mer 3 x Mer 3 1:0 of Mer 3: Other variants 
Or 
100% of offspring would be Mer 3. 
Table 3.3 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of wild-type and Mer 3 D. melanogaster. 
 
In the hybrid population of wild-type D. melanogaster and Mer 4 D. 
melanogaster there would be three possible parental combination as 
shown in the table below, each with a specific phenotypic ratio. 
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Parent Phenotype Phenotypic ratio of offspring expected 
Wild-Type x Wild-Type 1:0 of Wild-Type: Other variants 
Or 
100% of offspring would be Wild-Type. 
Wild-Type x Mer 4 1:0 of Wild-Type/Mer 4 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Wild-Type/Mer 4. 
Mer 4 x Mer 4 1:0 of Mer 4: Other variants 
Or 
100% of offspring would be Mer 4. 
Table 3.4 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of wild-type and Mer 4 D. melanogaster. 
 
The hybrid populations of wild-type and Mer 3 D. melanogaster, and 
wild-type and Mer 4 D. melanogaster bred to produce the second 
generation of these hybrid populations. The offspring from tables 3.3 
and 3.4 above reproduced, becoming the possible parental genotypes 
for generation 2.  
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Parent Phenotype Phenotypic ratio of offspring expected 
Wild-Type x Wild-
Type/Mer 3 Hybrid 
1:1 of Wild-Type: Wild-Type/Mer 3 
Hybrids 
Wild-Type x Mer 3 1:0 of Wild-Type/Mer 3 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Wild-Type/Mer 3. 
Wild-Type/Mer 3 
Hybrid x Mer 3 
1:1 of Mer 3: Wild-Type/Mer 3 Hybrids 
Table 3.5 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of wild-type and Mer 3 D. melanogaster bred to a second generation. 
 
Parent Phenotype Phenotypic ratio of offspring expected 
Wild-Type x Wild-
Type/Mer 4 Hybrid 
1:1 of Wild-Type: Wild-Type/Mer 4 
Hybrids 
Wild-Type x Mer 4 1:0 of Wild-Type/Mer 4 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Wild-Type/Mer 4. 
Wild-Type/Mer 4 
Hybrid x Mer 4 
1:1 of  
Mer 4: Wild-Type/Mer 4 Hybrids 
Table 3.6 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of wild-type and Mer 4 D. melanogaster bred to a second generation. 
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Mer 3 and Mer 4 D. melanogaster populations both had lethal, 
detrimental effects to phenotype and survival. Breeding of the two was 
difficult and any offspring that did get produced died during 
development. However, potential offspring of this mixed population is 
shown in table 3.7 below. 
 
Parent Phenotype Phenotypic ratio of offspring expected 
Mer 3 x Mer 4 1:0 of Mer 3/Mer 4 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Mer 3/Mer 4. 
Table 3.7 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of Mer 3 and Mer 4 D. melanogaster. 
 
Lastly the initial hybrid populations of wild-type and Mer 3 D. 
melanogaster, and wild-type and Mer 4 D. melanogaster were mixed. 
This population contained all three Mer variants. The population had 9 
possible parental phenotypes, taken from the offspring of the previous 
population, seen in table 3.3 and 3.4. 
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Parent Phenotype Phenotypic ratio of offspring expected 
Wild-Type x Wild-Type 1:0 of Wild-Type: Other variants 
Or 
100% of offspring would be Wild-Type. 
Wild-Type x Wild-
Type/Mer 4 Hybrid 
1:1 of Wild-Type: Wild-Type/Mer 4 
Hybrids 
Wild-Type x Mer 4 1:0 of Wild-Type/Mer 4 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Wild-Type/Mer 4. 
Wild-Type x Wild-
Type/Mer 3 Hybrid 
1:1 of Wild-Type: Wild-Type/Mer 3 
Hybrids 
Wild-Type/Mer 3 Hybrid 
x Wild-Type/Mer 4 
Hybrid 
1:1:1:1 of Wild-Type: Wild-Type/Mer 3 
Hybrids: Wild-Type/Mer 4 Hybrids: 
Mer3/Mer4 Hybrids 
Wild-Type/Mer 3 Hybrid 
x Mer 4 
1:1 of Wild-Type/Mer 4 Hybrids: Mer 
3/Mer 4 Hybrids 
Wild-Type x Mer 3 1:0 of Wild-Type/Mer 3 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Wild-Type/Mer 3. 
Wild-Type/Mer 4 Hybrid 1:1 of Wild-Type/Mer 3 Hybrids: Mer 
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x Mer 3 3/Mer 4 Hybrids 
Mer 3 x Mer 4 1:0 of Mer 3/Mer 4 Hybrids: Other 
variants 
Or 
100% of offspring would be 
heterozygous Mer 3/Mer 4. 
Table 3.8 – A table showing the parent phenotype and the phenotypic ratio of their offspring in a 
population of wild-type and Mer 4 D. melanogaster bred with wild-type and Mer 3 D. melanogaster. 
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DISCUSSION 
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4.1 General Discussion 
 
This study aimed to investigate the inheritance of genes associated 
with brain tumors in humans using a D. melanogaster model. Merlin 
has been shown to be an active protein with an extensive role within 
various aspects of the cells’ microenvironment (Zhou and Hanemann, 
2012).  It has been stated that a proteins’ functionality and role within 
a cell has much control over the rate of evolution, and the rate of 
change to that protein (Chakroborty et. al., 2015).  
The work by Chakroborty et. al., indicates that a protein, such as 
merlin, with its’ multitude of functions related to core biological 
process of division and growth should therefore be highly conserved 
with few mutations occurring over the generations. Disease related 
genes and non-disease genes were shown to have a variety of factors 
that affect evolutionary rate (Podder et. al., 2009). The study showed 
that non-disease genes were the most highly conserved and of those 
the ‘housekeeping’ genes were genes with the lowest rate for 
evolutionary change. Housekeeping genes are the genes involved the 
cells’ basic maintenance, and can be thought of as the minimal set of 
genes required to sustain life (Eisenberg and Levanon, 2013). 
Polygenic and Monogenic disease genes were both less conserved and 
of those two, polygenic was shown to be the least conserved and 
therefore most likely to be subject to mutation and evolutionary 
change (Podder et al., 2009). As a monogenic disease gene, merlin falls 
in the middle of the two showing some conservation but not a high 
amount, whilst also showing some evolutionary change and mutation. 
Lastly Podder et. al., ranked the factors that would produce a change 
with the proteins functionality being a restraint to oppose 
evolutionary change, as expected with example to the highly conserved 
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housekeeping proteins. However the mRNA levels were shown to have 
little restraint on the protein/genes’ conservation and that the change 
in expression level would therefore be the most likely factor to 
introduce evolutionary change to a protein (Podder et al., 2009). 
 
The initial three populations have been discussed above to show 
difficulty in breeding due to their mortality rate. Despite Mer 3 and 
Mer 4 being selected from a vast range of D. melanogaster mutants due 
to their relative success in survival and breeding. This study has shown 
it to be apparent that in D. melanogaster Merlin plays a crucial role to 
overall survival, shown by vast amounts of research indicating the 
multiple roles merlin has. 
 
4.2 Mendelian Genetics in the hybrid populations 
 
Two hybrid population of Wild-Type and Mer 3, and Wild-type and 
Mer 4 were produced from the initial three populations. The offspring 
of these two populations would contain individuals shown by their 
genotype in the table below. 
 
Potential Phenotypes of an 
individual in the hybrid 
population 
Two gene variants, one from 
each parent in hybrid 
population 
Wild-Type Homozygous Wild-Type Gene, Wild-Type 
Gene 
Heterozygous Wild-Type Gene, Mer 3 Gene 
Mer 3 Homozygous Mer 3 Gene, Mer 3 Gene 
Table 4.1 - Table showing the possible phenotypes of the offspring of the hybrid population and the 
two alleles they would have obtained from their parents.  
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An offspring of the hybrid population had either: two Mer 3 parents, 
two Wild-Type parents or one of each. Therefore, the offspring would 
be Mer 3 Homozygous, Wild-Type Homozygous or Heterozygous.  This 
can be seen by the family trees shown below. 
 
Figure 4.1 – Schematic family trees showing the potential pairing in the hybrid populations 
These family trees show an individual’s parentage and the potential 
alleles they have. Both Mer 3 and Mer 4 are represented as (A) and (B) 
respectively, in this image. 
This could also be represented as a punnetts square as shown below 
(Table 4.2-4.6). 
 Wt Wt 
Wt Wt Wt Wt Wt 
Wt Wt Wt Wt Wt 
Table 4.2 – A punnetts square showing the potential genotypes of the offspring produced when two 
wild-type D. melanogaster reproduce 
 
 Wt Wt 
M3 Wt M3 Wt M3 
M3 Wt M3 Wt M3 
Table 4.3– A punnetts square showing the potential genotypes of the offspring produced when a 
wild-type D. melanogaster and a Mer 3 D. melanogaster reproduce. 
 
Wt Wt 
Wt 
Wt M3 
WtxM3 
M3 M3 
M3 
Wt Wt 
Wt 
Wt M4 
WtxM4 
M4 M4 
M4 
A) 
B) 
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 M3 M3 
M3 M3 M3 M3 M3 
M3 M3 M3 M3 M3 
Table 4.4 - A punnetts square showing the potential genotypes of the offspring produced when two 
Mer 3 D. melanogaster reproduce. 
 
 Wt Wt 
M4 Wt M4 Wt M4 
M4 Wt M4 Wt M4 
Table 4.5 - A punnetts square showing the potential genotypes of the offspring produced when a 
wild-type D. melanogaster and a Mer 4 D. melanogaster reproduce. 
 
 M4 M4 
M4 M4 M4 M4 M4 
M4 M4 M4 M4 M4 
Table 4.6 - A punnetts square showing the potential genotypes of the offspring produced when two 
Mer 4 D. melanogaster reproduce. 
 
Loss of function alleles of Mer 3 and Mer 4 have been shown to be 
recessive traits (McCartney, et al., 2000). 
If one assumes that the no-mortality allele, Wild-Type is dominant over 
Mer 3 then the hybrid population would be 50% Wild-Type and 50% 
Mer 3 genotypically. The table below shows the outcome of three 
Punnett’s squares. A Punnett’s square shows two breeding individuals 
(Parents) and their 4 alleles, it then shows the genetic ratios of their 
offspring. 
The first generation of a breeding population has been shown to be the 
most susceptible to genomic erosion (Matusse et al, 2016).  This 
research focused on stocks of wreckfish, to determine the first-
generation genetic drift. The results showed that the stocks lost 26% of 
the genetic variation; despite the authors ensuring interbreeding was 
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kept minimal. This reduction was seen in 80% of the wreckfish 
populations at the first-generation. This research highlights the 
‘founder effect’, where the initial founders are the only individuals to 
provide genetic information and with no access to individuals outside 
the stock population, genomic erosion is difficult to avoid (Matusse et 
al, 2016).   
 
4.3 Wild-Type Population and Wild-Type Descendants 
 
The wild-type D. melanogaster populations would only ever produce 
wild-type offspring therefore 100% of the offspring would be wild-
type and of those 97% would survive to reproduce. With the wild-type 
allele being the allele that is the most viable this is expected that the 
highest survival rate and lowest mortality rate is seen in these 
individuals. Generation later the wild-type descendants showed an 
increase in mortality from 3% to 7%. This population was again only 
wild-type D. melanogaster and thus this change in survival could be 
due to random chance or genetic drift. In 1932 Sewell Wright produced 
his model of adaptive landscapes stating that genetic drift allowed as 
small population to have a large genetic variation and that natural 
selection would ’take over’ from genetic drift to evolve individuals or 
populations through an adaptive selective pressure. The image below 
shows Wright’s landscape model with valleys and peaks.  
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Figure 4.2 – An image showing the adaptive landscape model, showing valleys and peaks. Genetic 
drift is shown to fluctuate throughout the valley, whilst natural section can be seen as directional 
toward a peak. An example is shown within the image of the two peaks of natural selection showing 
butterflies with differing proboscis sizes and how this produces one more adapted than the other to 
feeding on the particular plant. Taken from MacNeill, 2017. 
 
Wright modeled that a valley was where a small population had much 
variation and genetic drift allowed movement throughout the valley, 
but once selective pressure had begun then natural selection began to 
move traits and individuals up towards a peak. Fixing them in a 
population and resulting in that population being unable to re-enter 
the valley again. This was shown in research of phenotypic evolution, 
where the authors discussed genetic drift allowing population on a 
peak to migrate from one peak to another through the uneven line of 
genetic drift (Engen and Saether, 2016). Genetic drift is the most likely 
of Mendelian genetics to have occurred in this wild-type population to 
result in the increased mortality rates in the descendant population 
showing once more the affect genetic drift can have on a small isolated 
population (Matusse et al., 2016).   
 Genetic differentiation can be produced through a population shifting 
from on peak to another by genetic drift or an epigenetic interaction 
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(Frank, 2011; Engen and Saether, 2016). The initial population of wild-
type D. melanogaster was used as the control and could be seen as the 
survival/mortality rate that is considered normal/average for D. 
melanogaster. 
 
4.4 Mer 3 and Mer 4 Populations 
 
The Mer 3 and Mer 4 populations showed high rates of mortality with 
the Mer 4 population showing the highest rate observed during this 
research with mortality rates at 73% 
 
4.5 Wild-Type and Mer 3 Hybrid Populations – Generation 1 & 2 
 
In the initial hybrid population of wild-type and Mer 3 there are three 
possible parent combinations (shown is table 3.3). From this there are 
potentially three outcomes for offspring. If one presumes that the 
parental couples are equally random to occur then each of the three 
potential offspring would encompass 33% of the population each. Each 
of these three population have their own mortality and survival rate. 
The 33% of offspring that are homozygous wild-types, the mortality 
rate is 3% this results in almost all of the 33% surviving and very little 
mortality. This is due to these individuals being phenotypically wild-
type with a high survival rate of 97%. The second 33% are 
homozygous Mer 3 individuals and their mortality rate is much higher 
as seen in table 3.1. The mortality rate of the Mer 3 population is 66%, 
meaning that only 34% or one third survive. If one third of the 33% 
survive, then only 11% of the individuals survive to adult. Therefore of 
the 66% discussed 44% of those individuals survived. The true 
mortality rate as a shown in table 3.1 for the wild-type and Mer 3 
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crossed population is 45% resulting in 55% surviving. This means the 
difference between the 44% calculated and the 55% total is the 
survival rate of heterozygous wild-type and Mer 3 individuals. 
Therefore, the survival rate of heterozygotes is 11% out of a possible 
33%, resulting in approximately one third of heterozygotes surviving 
and two thirds dying. The mortality rate of the heterozygotes is 66%. 
This has shown that heterozygote D. melanogaster have the same 
survival rate as the D. melanogaster which are homozygous for Mer 3, 
as both have a decreased survival rate. 
 
Generation two of this Mer 3 and wild-type hybrid population had a 
mortality rate of 39% as shown in table 3.1. The potential phenotypic 
ratios can be seen in table 3.5. If the three possible ratios are equally 
likely to randomly occur then similarly to above each represents 33% 
of the entire population. The first 33% would result in a 1:1 ratio of a 
homozygous wild-type individual and a heterozygous individual whom 
are both equally likely to occur, representing 16.5% of the entire 
population (100%) each. The homozygous wild-type would again have 
a low mortality rate of 3%, where 97% survive. Whereas, the 
heterozygote would have 66% mortality rate and thus only 5.5% of a 
possible 16.5% would survive. The second 33% results in a 1:1 ratio of 
a homozygote Mer 3 individual and a heterozygote. Whom both have a 
mortality rate of 66%, resulting in only 11% of the 33% surviving. 
Lastly the third 33% would result in all individuals being 
heterozygotes wild-type and Mer 3 individuals. These again have a 
mortality rate of 66%, resulting in 11% of this 33% surviving. 
Ultimately the expected survival rate of this second generation is 44%. 
However, table 3.1 shows that the survival rate is in fact 61%. This 
may be the result of the three potential parental couplings not being 
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equally distributed and that the D. melanogaster are selectively 
breeding, choosing mates based on their fecundity and the potential 
offspring they could produce, following natural selection as opposed to 
random chance by neutral selection and genetic drift. This suggests 
that the D. melanogaster are selecting mates that are most likely to 
produce offspring that will survive, therefore naturally selecting the 
wild-type D. melanogaster. 
4.6 Wild-Type and Mer 4 Hybrid Populations – Generation 1 & 2 
 
In the initial hybrid population of wild-type and Mer 4 there are three 
possible parent combinations (shown is table 3.3). From this there are 
potentially three outcomes for offspring. If one presumes that the 
parental couples are equally random to occur then each of the three 
potential offspring would encompass 33% of the population each. Each 
of these three population have their own mortality and survival rate. 
The 33% of offspring that are homozygous wild-types, the mortality 
rate is 3% this results in almost all of the 33% surviving and very little 
mortality. This is due to these individuals being phenotypically wild-
type with a high survival rate of 97%. The second 33% are 
homozygous Mer 4 individuals and their mortality rate is much higher 
as seen in table 3.1. The mortality rate of the Mer 4 population is 73%, 
meaning that only 27% or approximately one quarter survive. If one 
quarter of the 33% survive, then only 8.3% of the individuals survive 
to adult. Therefore of the 66% discussed 41.3% of those individuals 
survived. The true mortality rate as a shown in table 3.1 for the wild-
type and Mer 4 crossed population is 44% resulting in 56% surviving. 
This means the difference between the 41.3% calculated and the 56% 
total is the survival rate of heterozygous wild-type and Mer 3 
individuals. Therefore, the survival rate of heterozygotes is 15% out of 
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a possible 33%, resulting in approximately half of heterozygotes 
surviving and half dying. The mortality rate of the heterozygotes is 
approximately 50%. 
This has shown that heterozygote D. melanogaster have a lower 
mortality rate than the D. melanogaster which are homozygous for Mer 
4. 
 
Generation two of this Mer 4 and wild-type hybrid population had a 
mortality rate of 19% as shown in table 3.1. The potential phenotypic 
ratios can be seen in table 3.6. If the three possible ratios are equally 
likely to randomly occur then similarly to above each represents 33% 
of the entire population. The first 33% would result in a 1:1 ratio of a 
homozygous wild-type individual and a heterozygous individual whom 
are both equally likely to occur, representing 16.5% of the entire 
population (100%) each. The homozygous wild-type would again have 
a low mortality rate of 3%, where 97% survive. Whereas, the 
heterozygote would have 50% mortality rate and thus only 8.3% of a 
possible 16.5% would survive. The second 33% results in a 1:1 ratio of 
a homozygote Mer 4 individual and a heterozygote. The homozoygous 
Mer 4 individual has a quarter survival rate meaning that 4% of the 
potential 16% survive. The heterozygote has a 50% mortality rate 
meaning 8.3% would survive. Lastly the third 33% would result in all 
individuals being heterozygotes wild-type and Mer 4 individuals. 
These have a mortality rate of 50%, resulting in 16.5% of this 33% 
surviving. Ultimately the expected survival rate of this second 
generation is 53.6%. However, table 3.1 shows that the survival rate is 
in fact 81%. This may be the result of the three potential parental 
couplings not being equally distributed and that the D. melanogaster 
are selectively breeding, choosing mates based on their fecundity and 
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the potential offspring they could produce, following natural selection 
as opposed to random chance by neutral selection and genetic drift. 
This suggests that the D. melanogaster are selecting mates that are 
most likely to produce offspring that will survive, therefore naturally 
selecting the wild-type D. melanogaster. 
 
4.7 The population containing all three variants (Wild-Type, Mer 
3 and Mer 4) 
 
This last population, which was a hybrid population of the previous 
two hybrid populations, a double hybrid, contained all three merlin 
alleles (Wild-Type, Mer 3 and Mer 4) within the gene pool of the 
population. An individual of this population may have had two of its’ 
grandparents as pure Wild-Type alleles, one grandparent of pure Mer 
3 and the fourth grandparent as pure Mer 4.  The potential genotypes 
of the individuals in this double hybrid are shown in the table below 
with their 4 grandparent’s phenotypes. 
 
(Potential) Alleles of an 
individual of the double hybrid 
population 
(Wt = Wild-Type, M3 = Mer 3, 
M4 = Mer 4) 
Four grandparents of the 
individual 
Wt Wt Four Wild-Type 
Wt M4 Two Wild-Type and Two Mer 4 
Wt (Wt or M4) Three Wild-Type and One Mer 4 
Wt (Wt or M3) Three Wild-Type and One Mer 3 
M4 (Wt or M3) One Wild-Type, One Mer 3and 
Two Mer 4 
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(Wt or M3) (Wt or M4) Two Wild-Type, One Mer 3 and 
One Mer 4 
Wt M3 Two Wild-Type and Two Mer 3 
M3 M4 Two Mer 3 and Two Mer 4 
M3 (Wt or M4) One Wild-Type, One Mer 4and 
Two Mer 3 
Table 4.7 – This table shows the potential or known alleles of an individual depending on their 
grandparent’s phenotype. 
 
These nine potential offspring are also shown in table 3.8. If the nine 
phenotypic ratios are equally likely to occur then they each represent 
approximately 11% of the overall population. The first 11% would be 
100% homozygous wild-type. The second would result in a 1:1 ratio of 
homozygous wild-type to heterozygous Mer 4 and wild-type D. 
melanogaster. The third would be 100% heterozygous Mer 4 and wild-
type D. melanogaster. The fourth would result in a 1:1 ratio of 
homozygous wild-type to heterozygous Mer 3 and wild-type D. 
melanogaster. The fifth would result in a 1:1:1:1 ratio of homozygous 
wild-type: heterozygous Mer 3 and wild-type: heterozygous Mer 4 and 
wild-type: heterozygous Mer 3 and Mer 4. The sixth would result in a 
1:1 ratio of heterozygous Mer 4 and wild-type, and heterozygous Mer 3 
and Mer 4.  The seventh would be 100% heterozygous Mer 3 and wild-
type D. melanogaster. The eight 11% would be a 1:1 ratio of 
heterozygous Mer 4 and wild-type, and a heterozygous Mer 3 and Mer 
4. The last 11% would result in 100% heterozygous Mer 3 and Mer 4 
Individuals. Note that heterozygous individuals with Mer 3 and Mer 4 
genes were not viable and did not develop into adults. Using the 
mortality rates and survival rates from table 3.1 and Section 4.5 and 
4.6. The overall mortality rate of this population is calculated to be 
approximately 56% with the survival rate at 44%. However, table 3.1 
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shows that the true mortality rate is 13% and the survival rate is 87%. 
This is drastically higher than expected and this is likely due to the 
suggestion made in the previous two section (4.5 and 4.6). This 
suggestion inferred that the D. melanogaster are selecting mates based 
on natural selection and their ability to produce many viable offspring. 
This seem to also be the case see here with the survival rate double 
that which is expected. 
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4.6 Conclusion 
 
In conclusion, this methodology has highlighted the lethal nature of 
mutants for merlin, particularly those previously addressed as 
recessive and detrimental to D. melanogaster. All populations showed 
evidence that natural selection was occurring within the populations 
and that genes associated with cancer phenotypes such as merlin in 
this research are subject to natural selection and are indicated to be 
lost via breeding within a population. 
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4.7 Future Work 
 
Research into cancer genes is increasing often, with more data and 
theories available. It is important that the model organisms used is 
viable and can produce increased reliability and usable data. Using 
other models than D. melanogaster would be useful for this type of 
research. Using mouse models would improve experimentation due to 
the mouse being a closer model to humans. Eventually using a human 
model itself, mapping the merlin variation throughout the population, 
within genetic clusters (races).  Mapping the variation within the 
human population would be the next step to this research, specifically 
if individuals of varying demographic ancestry e.g. mixed race 
individuals, would allow an inheritance pattern to be mapped for the 
human population, confirming the genetic drift and natural selection 
discussed in this thesis.  A similar model using D. melanogaster could 
be used for other proteins. This research focused on monogenic 
diseases, but many diseases like cancer are the result of polygenic 
interactions, many proteins becoming non-functional, again further 
research into more proteins and the interactions they create would 
benefit the literature, possibly even producing a prevention or 
treatment in the future. A useful form of treatment for lethal alleles 
within the population would be gene therapy, introducing the normal/ 
functioning allele into an individual with a mutant or non-functioning 
allele. Further to this immunotherapeutic avenues could be 
considered, with the use of antibodies toward mutant merlin 
(McGranahan et al., 2017).  
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